Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | LIPE | Q05469 | 1/20 | 0.33 |
| ▸ | CPN1 | P15169 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15324652 | 1.00 | ITGB3 (0.37) | ITGB3ITGA2BALDH1A1LMNAEPHX2 | |
| SCHEMBL16973175 | 1.00 | ITGB3 (0.37) | ITGB3ITGA2BALDH1A1LMNAEPHX2 | |
| SCHEMBL25335914 | 0.88 | TACR3 (0.39) | ITGB3ITGA2BALDH1A1LMNAKDM4E | |
| SCHEMBL2352547 | 0.88 | TACR3 (0.39) | ITGB3ITGA2BALDH1A1LMNAKDM4E | |
| SCHEMBL29245349 | 0.88 | TACR3 (0.39) | ITGB3ITGA2BALDH1A1LMNAKDM4E | |
| SCHEMBL2347493 | 0.85 | AKR1C3 (0.36) | ITGB3ITGA2BALDH1A1LMNAEPHX2 | |
| SCHEMBL21049974 | 0.83 | CYP4F2 (0.39) | ALDH1A1LMNAEPHX2SMN1; SMN2MEN1 | |
| SCHEMBL1777738 | 0.82 | EPHX2 (0.48) | ALDH1A1EPHX2SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL3329964 | 0.82 | EPHX2 (0.48) | ALDH1A1EPHX2SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL1183595 | 0.82 | EPHX2 (0.48) | ALDH1A1EPHX2SMN1; SMN2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4103564-A1 | P2X3 MODULATORS | Bellus Health Cough Inc. (CA) | 2022-12-21 | — | — | EP | disclosed |
| WO-2021161105-A1 | P2X3 MODULATORS | BELLUS HEALTH COUGH INC. (CA) | 2021-08-19 | — | — | WO | disclosed |
| EP-3765458-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | Biogen MA Inc. (US) | 2021-01-20 | — | — | EP | disclosed |
| WO-2019178191-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. (US) | 2019-09-19 | — | — | WO | disclosed |
| EP-3507283-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE OR INFLAMMATORY DISEASES OR CANCERS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2019-07-10 | — | — | EP | disclosed |
| WO-2018041947-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE OR INFLAMMATORY DISEASES OR CANCERS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-03-08 | — | — | WO | disclosed |
| US-20170334899-A1 | AMINO-SUBSTITUTED ISOTHIAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-23 | — | — | US | disclosed |
| EP-3246030-A1 | NOVEL ADENINE DERIVATIVES | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | disclosed |
| EP-2320905-B1 | NOVEL ADENINE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2017-06-28 | — | — | EP | disclosed |
| CN-102176911-B | Novel adenine derivatives | GLAXOSMITHKLINE LLC | 2014-12-10 | — | — | CN | disclosed |
| US-8802684-B2 | Adenine derivatives | GLAXOSMITHKLINE LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140024664-A1 | NOVEL ADENINE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2014-01-23 | — | — | US | disclosed |
| US-8563717-B2 | Adenine derivatives | GLAXOSMITHKLINE LLC (US) | 2013-10-22 | — | — | US | disclosed |
| CN-102176911-A | Novel adenine derivatives | GLAXOSMITHKLINE LLC | 2011-09-07 | — | — | CN | disclosed |
| US-20100056523-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-7625890-B2 | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors | SMITHKLINE BEECHAM CORP. (US) | 2009-12-01 | — | — | US | disclosed |
| WO-2008063853-A2 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2008-05-29 | — | — | WO | disclosed |
| US-20080076763-A1 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076763-A1 | Inhibitors of Akt activity | PI4KB, PIK3CA, AKT2 | ITGB3 3387/4885ITGA2B 1964/4885ALDH1A1 4166/4885 |
| US-20100056523-A1 | INHIBITORS OF AKT ACTIVITY | PI4KB, PIK3CA, AKT2 | ITGB3 3387/4885ITGA2B 1964/4885ALDH1A1 4166/4885 |
| US-20140024664-A1 | NOVEL ADENINE DERIVATIVES | IFNAR1, STING1, IFNG | ITGB3 3769/4885ITGA2B 3918/4885ALDH1A1 1680/4885 |
| US-20170334899-A1 | AMINO-SUBSTITUTED ISOTHIAZOLES | BRCA1, TP53, SULT2A1 | ITGB3 1587/4885ITGA2B 1993/4885ALDH1A1 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.